Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma

Pazopanib has been approved for treating soft tissue sarcomas (STS) after chemotherapy. We aimed to evaluate the prognostic factors, clinical outcomes, and tolerability of pazopanib in patients with STS. Forty-five patients treated between June 2015 and August 2019 were reviewed. Clinical outcome wa...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2021, Vol.13, p.6755-6766
Main Authors: Alshamsan, Bader, Badran, Ahmad, Alshibany, Aisha, Maraiki, Fatma, Elshenawy, Mahmoud A, Elhassan, Tusneem, Atallah, Jean Paul
Format: Article
Language:English
Subjects:
a tyrosine kinase inhibitor
Anemia
Antimitotic agents
Antineoplastic agents
asps
Cancer
Care and treatment
Chemotherapy
Clinical outcomes
Development and progression
Disease control
dt/af
Growth factors
Hypertension
Hypothyroidism
Liposarcoma
lms
Medical prognosis
Medical research
Medicine, Experimental
Metastasis
Original Research
Patient outcomes
Patients
pazopanib
Sarcoma
saudi arabia
Statistical analysis
sts
Survival analysis
Targeted cancer therapy
Terminology
Thyroid hormones
Tumors
ups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pazopanib has been approved for treating soft tissue sarcomas (STS) after chemotherapy. We aimed to evaluate the prognostic factors, clinical outcomes, and tolerability of pazopanib in patients with STS. Forty-five patients treated between June 2015 and August 2019 were reviewed. Clinical outcome was measured by assessing the disease control rate (DCR) using Response Evaluation Criteria in Solid Tumors (version 1.1). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Adverse effects were assessed using the Common Terminology Criteria for Adverse Events (version 5.0). The median age of patients at diagnosis was 28 (interquartile range (IQR), 23-45) years. Pazopanib was used as the second-line treatment in 46.7% and the subsequent line in 53.3% of patients. The overall DCR was 55.6%, and at 8 and 12 weeks, it was 52.3% and 35.5%, respectively; the median duration of response was 7 (IQR: 2-18) months. Pazopanib-induced hypothyroidism was associated with DCR, with an odds ratio of 7 (95% confidence interval [95% CI: 1.7-27.5], p
ISSN:1179-1322
1179-1322
DOI:10.2147/CMAR.S323499